ClinicaliQ Trial Snapshot
- Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) — Active Not Recruiting • Phase III • NCT06564142.
- Povetacicept reduced proteinuria and slowed kidney decline in adults with IgA nephropathy compared to placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function. Conditions: Immunoglobulin A Nephropathy Interventions: Povetacicept, Placebo (matched to Povetacicept) Lead Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex Planned Enrollment: 605 participants